Megan L. Peach

Megan L. Peach

Auto-generated profile, based on publicly available information

Megan L. Peach

Basic Science Program, Leidos Biomedical Research, Inc., Chemical Biology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2014 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
AZAlexey V. Zakharov
Alexey V. Zakharov
MPMegan L. Peach
Megan L. Peach
MSMarkus Sitzmann
Markus Sitzmann
MNMarc C. Nicklaus
Marc C. Nicklaus
Many of the structures in PubChem are annotated with activities determined in high-throughput screening (HTS) assays. Because of the nature of these assays, the activity data are typically strongly imbalanced, with a small number of active compounds contrasting with a very large number of inactive compounds. We have used several such imbalanced PubChem HTS assays to test and develop strategies to efficiently build robust QSAR models from imbalanced data sets. Different descriptor types [Quantitative Neighborhoods of Atoms (QNA) and “biological” descriptors] were used to generate a variety of QSAR models in the program GUSAR. The models obtained were compared using external test and validation sets. We also report on our efforts to incorporate the most predictive of our models in the publicly available NCI/CADD Group Web services (http://cactus.nci.nih.gov/chemical/apps/cap).

30 June 2010 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
NONaoya Oku
Naoya Oku
KTKentaro Takada
Kentaro Takada
RFRichard W. Fuller
Richard W. Fuller
JWJennifer A. Wilson
Jennifer A. Wilson
MPMegan L. Peach
Megan L. Peach
Kirk GustafsonKirk Gustafson
Kirk Gustafson

1 August 2008 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
PBPeter M Blumberg
Peter M Blumberg
NKN. Kedei
N. Kedei
NLN. E. Lewin
N. E. Lewin
DYD. Yang
D. Yang
GCG. Czifra
G. Czifra
VMV .E. Marquez
V .E. Marquez
The diacylglycerol-responsive C1 domains of protein kinase C and of the related classes of signaling proteins represent highly attractive targets for drug development. The signaling functions that are regulated by C1 domains are central to cellular control, thereby impacting many pathological conditions. Our understanding of the diacylglycerol signaling pathways provides great confidence in the utility of intervention in these pathways for treatment of cancer and other conditions. Multiple compounds directed at these signaling proteins, including compounds directed at the C1 domains, are currently in clinical trials, providing strong validation for these targets. Extensive understanding of the structure and function of C1 domains, coupled with detailed insights into the molecular details of ligand – C1 domain interactions, provides a solid basis for rational and semi-rational drug design. Finally, the complexity of the factors contributing to ligand – C1 domain interactions affords abundant opportunities for manipulation of selectivity; indeed, substantially selective compounds have already been identified.

11 November 2020 in Scientific Data
Verified
Journal Article
Open access
PDF file
HPHitesh Patel
Hitesh Patel
WIWolf-Dietrich Ihlenfeldt
Wolf-Dietrich Ihlenfeldt
PJPhilip N. Judson
Philip N. Judson
YMYurii S. Moroz
Yurii S. Moroz
YPYuri Pevzner
Yuri Pevzner
MNMarc C. Nicklaus
Marc C. Nicklaus
We have made available a database of over 1 billion compounds predicted to be easily synthesizable, called Synthetically Accessible Virtual Inventory (SAVI). They have been created by a set of transforms based on an adaptation and extension of the CHMTRN/PATRAN programming languages describing chemical synthesis expert knowledge, which originally stem from the LHASA project. The chemoinformatics toolkit CACTVS was used to apply a total of 53 transforms to about 150,000 readily available building blocks (enamine.net). Only single-step, two-reactant syntheses were calculated for this database even though the technology can execute multi-step reactions. The possibility to incorporate scoring systems in CHMTRN allowed us to subdivide the database of 1.75 billion compounds in sets according to their predicted synthesizability, with the most-synthesizable class comprising 1.09 billion synthetic products. Properties calculated for all SAVI products show that the database should be well-suited for drug discovery. It is being made publicly available for free download from https://doi.org/10.35115/37n9-5738.

15 January 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MPMegan L. Peach
Megan L. Peach
NTNelly Tan
Nelly Tan
SCSarah J. Choyke
Sarah J. Choyke
Alessio GiubellinoAlessio Giubellino
Alessio Giubellino
GAGagani Athauda
Gagani Athauda
DBDonald Bottaro
Donald Bottaro

6 February 2012 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
MSMarkus Sitzmann
Markus Sitzmann
IWIwona E. Weidlich
Iwona E. Weidlich
IFIgor V. Filippov
Igor V. Filippov
CLChenzhong Liao
Chenzhong Liao
MPMegan L. Peach
Megan L. Peach
MNMarc C. Nicklaus
Marc C. Nicklaus
We present here a greatly updated version of an earlier study on the conformational energies of protein–ligand complexes in the Protein Data Bank (PDB) [Nicklaus et al. Bioorg. Med. Chem. 1995, 3, 411–428], with the goal of improving on all possible aspects such as number and selection of ligand instances, energy calculations performed, and additional analyses conducted. Starting from about 357,000 ligand instances deposited in the 2008 version of the Ligand Expo database of the experimental 3D coordinates of all small-molecule instances in the PDB, we created a “high-quality” subset of ligand instances by various filtering steps including application of crystallographic quality criteria and structural unambiguousness. Submission of 640 Gaussian 03 jobs yielded a set of about 415 successfully concluded runs. We used a stepwise optimization of internal degrees of freedom at the DFT level of theory with the B3LYP/6-31G(d) basis set and a single-point energy calculation at B3LYP/6-311++G(3df,2p) after each round of (partial) optimization to separate energy changes due to bond length stretches vs bond angle changes vs torsion changes. Even for the most “conservative” choice of all the possible conformational energies—the energy difference between the conformation in which all internal degrees of freedom except torsions have been optimized and the fully optimized conformer—significant energy values were found. The range of 0 to ∼25 kcal/mol was populated quite evenly and independently of the crystallographic resolution. A smaller number of “outliers” of yet higher energies were seen only at resolutions above 1.3 Å. The energies showed some correlation with molecular size and flexibility but not with crystallographic quality metrics such as the Cruickshank diffraction-component precision index (DPI) and Rfree-R, or with the ligand instance-specific metrics such as occupancy-weighted B-factor (OWAB), real-space R factor (RSR), and real-space correlation coefficient (RSCC). We repeated these calculations with the solvent model IEFPCM, which yielded energy differences that were generally somewhat lower than the corresponding vacuum results but did not produce a qualitatively different picture. Torsional sampling around the crystal conformation at the molecular mechanics level using the MMFF94s force field typically led to an increase in energy.